Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)

作者全名："Rong, Li; Zou, Junyan; Ran, Wei; Qi, Xiaohong; Chen, Yaokai; Cui, Hongjuan; Guo, Jinjun"

作者地址："[Rong, Li; Guo, Jinjun] Chongqing Med Univ, Bishan Hosp, Dept Gastroenterol, Chongqing, Peoples R China; [Zou, Junyan; Cui, Hongjuan] Southwest Univ, Med Res Inst, Chongqing, Peoples R China; [Zou, Junyan; Ran, Wei; Chen, Yaokai] Southwest Univ, Publ Hlth Hosp, Med Res Inst, Chongqing, Peoples R China; [Qi, Xiaohong] Baoshan Peoples Hosp Yunnan Prov, Dept Gen Surg, Baoshan, Yunnan, Peoples R China"

通信作者："Guo, JJ (通讯作者)，Chongqing Med Univ, Bishan Hosp, Dept Gastroenterol, Chongqing, Peoples R China."

来源：FRONTIERS IN ENDOCRINOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000921524600001

JCR分区：Q2

影响因子：5.2

年份：2023

卷号：13

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：nonalcoholic fatty liver disease; non-alcoholic steatohepatitis; diet; exercise; medical treatment

摘要："Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. In order to more accurately reflect its pathogenesis, an international consensus renamed NAFLD in 2020 as metabolic (dysfunction) associated with fatty liver disease (MAFLD). The changes in diet and lifestyle are recognized the non-drug treatment strategies; however, due to the complex pathogenesis of NAFLD, the current drug therapies are mainly focused on its pathogenic factors, key links of pathogenesis, and related metabolic disorders as targets. There is still a lack of specific drugs. In clinical studies, the common NAFLD treatments include the regulation of glucose and lipid metabolism to protect the liver and anti-inflammation. The NAFLD treatments based on the enterohepatic axis, targeting gut microbiota, are gradually emerging, and various new metabolism-regulating drugs are also under clinical development. Therefore, this review article has comprehensively discussed the research advancements in NAFLD treatment in recent years."

基金机构："Chongqing Medical Scientific Research Project (Joint Projectof Chongqing Health Commission and Science and Technology Bureau) [2022GDRC019]; Chongqing Natural Science Foundation [CSTB2022NSCQ-MSX1257, cstc2019jcyj-msxmX0752, cstc2018jcyj-AX0006]"

基金资助正文："Chongqing Medical Scientific Research Project (Joint Project of Chongqing Health Commission and Science and Technology Bureau) (2022GDRC019) and Chongqing Natural Science Foundation (CSTB2022NSCQ-MSX1257, cstc2019jcyj-msxmX0752, cstc2018jcyj-AX0006)."